

Board

Wissing K.M. (President)
Roeyen G. (UA) (Past President)
Jacobs-Tulleneers-Thevissen D. (VUB) (Secretary)
Meurisse N. (ULG) (Treasurer)
Van Raemdonck D., Van Cleemput J. (KUL)
Roeyen G., Hartman V. (UA)
Mourad M., Van Caenegem O. (UCL)
Van Belleghem Y., Randon C. (UG)
Antoine M., Mikhalski D. (ULB)
Meurisse N., Weekers L. (ULG)
Wissing K.M., Jacobs-Tulleneers-Thevissen D. (VUB)
R. Surin (ULB), P. Hollants (UA) (Transplant Coordinator Section)

Organ Advisory

Committees Delegates

Be-KPAC

G. Roeyen (UA), L. Weekers (Ulg)

Be-ThAC

Van Belleghem (UG), Van Raemdonck D. (KUL)

Be-LIAC

Detry O. (ULG), Pirenne J. (KUL)

Be-OPC

D. Ledoux (UCL), A. De Grauwe (VUB)

BTNS

Breunig C. (President), Dereyck Ch. (Secretary)

4 March 2021

Dear members of the Belgian Hematology Society,

Epstein-Barr virus-associated post-transplant lymphoproliferative disease (PTLD) in transplant recipients is a condition with poor prognosis and high mortality, particularly after failure of first line therapy with rituximab and/or chemotherapy.

Tabelecleucel is an allogeneic T cell immunotherapy active against EBV in an HLA-restricted manner that has been developed by ATARA Biotherapeutics as a promising innovative therapy for patients with EBV-associated PTLT.

Tabelecleucel will be tested in the prospective single arm phase III ALLELE study in solid organ transplant recipients and hematopoietic cell transplant patients with EBV-associated PTLT and failed previous treatment with rituximab and/or chemotherapy.

To inform transplant professionals about tabelecleucel and the ALLELE study in Belgium, the BTS board has decided to organize a symposium on EBV-associated PTLT. Objectives are to provide an up to date overview on the diagnosis and therapy of the condition as well as information about tabelecleucel and the design of the ALLELE study.

Only a small number of centers will participate in the study in Belgium. The symposium will create an opportunity to meet investigators who might be contacted for inclusion of patients into the study.

The BTS **webinar "Innovative therapies of EBV-associated PTLT"** will be organized as a Zoom meeting on Mar 23, 2021 06:00 PM Brussels time.

Participants can register for free under the following link:

https://us02web.zoom.us/webinar/register/WN_sTG4L7CUSM6kgEXj2IUfFg

Program:

- Introduction and presentation of the speakers by the BTS president (5 minutes)
- Overview of PTLT with a focus on EBV-associated post-transplant PTLT and review of the available therapies (Pr. Daan Dierickx; Hematology Department UZ Leuven) (20 minutes)
- MHC restricted antigen-specific T cell lines developed by Atara Biotherapeutics with focus on mechanism of action and therapeutic use. (Willis Navarro MD; VP of Clinical Research and Development; Atara Biotherapeutics) (20 minutes)
- Innovative anti-EBV T cell therapies (tabelecleucel) as therapy for Epstein-Barr Virus-associated Post-Transplant Lymphoproliferative Disease. Presentation of the ALLELE study (Prof. Sophie Servais; Hematology Department CHU Liège) (20 minutes)
- Questions and answers (15 minutes)

Short biography of the speakers:

Prof Dr. Daan Dierickx is working as a hematologist in the Department of Hematology at the University Hospitals Leuven. His main clinical areas of interest include rare aggressive lymphoproliferative disorders, immune mediated hematological disorders and apheresis. He is also head of the Laboratory of Experimental Hematology at the Catholic University Leuven, where he mainly focuses on unraveling the pathogenic mechanisms of rare lymphoproliferative disorders (in particular posttransplant lymphomas), aiming to identify new potential therapeutic targets.

Prof Dr. Sophie Servais is currently working as clinical hematologist (transplantation and cell therapy department) at the CHU of Liège and as post-doctoral Researcher of the Belgian Foundation against Cancer at the University of Liege. Her work is dedicated to allogeneic stem cell transplantation, and more specifically on the impact of graft source and graft composition on outcomes after stem cell transplantation. Additional fields of interest are immune reconstitution and graft-versus-host disease after allogeneic stem cell transplantation as well as novel cell therapies (such as CAR T cells).

This meeting is organized with financial support by ATARA BIOTHERAPEUTICS (www.atarabio.com)

For the BTS board,

Karl Martin Wissing, , PhD
Daniel Jacobs, MD, PhD
Nicolas Meurisse, MD, PhD